Document Detail


Is the abundance of Faecalibacterium prausnitzii relevant to Crohn's disease?
MedLine Citation:
PMID:  20695899     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Reports that bacteria within the Firmicutes phylum, especially the species Faecalibacterium prausnitzii, are less abundant in Crohn's disease (CD) patients and supernatants from cultures of this bacterium are anti-inflammatory prompted the investigation of the possible correlations between the abundance of F. prausnitzii and the response to treatment in patients with gut diseases and healthy controls. In a randomized, double-blind trial, faeces were collected from healthy volunteers, and from patients with active CD, ulcerative colitis (UC) and irritable bowel syndrome before and after treatment. The levels of F. prausnitzii DNA in faecal suspensions were determined by PCR. Treatment by an elemental diet was effective, resulting in decreases in both the Harvey and Bradshaw index (P<0.001) and the concentrations of serum C-reactive protein (P<0.05). The total levels of F. prausnitzii in faecal samples from CD patients at presentation were lower than those in the other groups both before and after the treatment. There was no correlation between F. prausnitzii abundance and the severity of CD before treatment. Clinical improvement unexpectedly correlated with a significant decrease in the abundance of F. prausnitzii, especially the A2-165 subgroup (P<0.05). Our data suggest that a paucity of F. prausnitzii in the gastrointestinal microbial communities is likely to be a minor aetiological factor in CD: recovery following elemental diet is attributed to lower levels of gut flora.
Authors:
Wenjing Jia; Rebekah N Whitehead; Lesley Griffiths; Claire Dawson; Rosemary H Waring; David B Ramsden; John O Hunter; Jeffrey A Cole
Related Documents :
21249399 - Pediatric patients with a malignant bone tumor: when does functional assessment make se...
843139 - Enterocolitis with peritonitis in a child with pheochromocytoma.
12790919 - Histological changes associated with the use of intravenous cyclosporin in the treatmen...
21883679 - Airway dimensions and pulmonary function in chronic obstructive pulmonary disease and b...
1848619 - Cytomegalovirus colitis in aids: presentation in 44 patients and a review of the litera...
11149559 - Glomerular and tubular renal functions after long-term medication of sulphasalazine, ol...
24398659 - Asymmetric postural tremor preceding dopa-responsive parkinsonism - the transition dise...
11079539 - Nbi-5788, an altered mbp83-99 peptide, induces a t-helper 2-like immune response in mul...
21564439 - Clinical significance of anaemia associated with prolactin-secreting pituitary tumours ...
Publication Detail:
Type:  Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't     Date:  2010-07-08
Journal Detail:
Title:  FEMS microbiology letters     Volume:  310     ISSN:  1574-6968     ISO Abbreviation:  FEMS Microbiol. Lett.     Publication Date:  2010 Sep 
Date Detail:
Created Date:  2010-08-24     Completed Date:  2011-01-04     Revised Date:  2013-05-29    
Medline Journal Info:
Nlm Unique ID:  7705721     Medline TA:  FEMS Microbiol Lett     Country:  England    
Other Details:
Languages:  eng     Pagination:  138-44     Citation Subset:  IM    
Affiliation:
School of Biosciences, University of Birmingham, Birmingham, UK.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Colitis, Ulcerative / microbiology
Crohn Disease / diet therapy*,  microbiology*
Feces / microbiology
Food, Formulated*
Gram-Positive Bacteria / genetics,  physiology*
Irritable Bowel Syndrome / microbiology
Severity of Illness Index
Treatment Outcome
Grant Support
ID/Acronym/Agency:
WT080238MA//Wellcome Trust
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Identification of candidate proteins for the diagnosis of Bartonella henselae infections using an im...
Next Document:  The F plasmid transfer activator TraJ is a dimeric helix-turn-helix DNA-binding protein.